Clinical Trial Update: Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing natalizumab and fingolimod in relapsing-remitting multiple sclerosis was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)
• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2017-06-09